Oral contraceptives highlight the genotype-specific association between serum phospholipids and activated factor VII

Autor: Giovanna Marchetti, M. Samama, Gualtiero Mariani, F. Ceci, H. Prydz, Rogier M. Bertina, V. Vicente Garcia, M. Puopolo, Jacqueline Conard, R. Poso, Francesco Bernardi, G. D. Di Nucci, M. V. Ciarla, Per Morten Sandset
Rok vydání: 1999
Předmět:
Zdroj: Scopus-Elsevier
ISSN: 1079-5642
Popis: Abstract —The present analysis was undertaken to study the effect of oral contraceptive (OC) use on activated factor VII (FVIIa) in subjects characterized by FVII genotypes, with the further aim of evaluating the role of lipids in this pharmacological interaction. In OC users (n=42) and nonusers (n=130) of comparable age, we examined the FVII phenotypic variables (FVII coagulant activity [FVIIc], FVII antigen, and FVIIa), FVII genotypes (the 353R/Q and 5′F7 polymorphisms analyzed in combination; alleles M1 / M2 and A1 / A2 , respectively), and a number of lipid and lipoprotein parameters: serum concentrations of total cholesterol (chol), low density lipoprotein and high density lipoprotein-chol, triglycerides, phospholipids (PhLs), apolipoprotein A1, and lipoprotein(a). PhLs, triglycerides, apolipoprotein A1, chol, FVII antigen, FVIIc, and high density lipoprotein-chol levels were shown to be statistically higher in users than nonusers. FVII levels, particularly those of FVIIa and FVIIc, were much higher in homozygotes for the A1 and M1 alleles ( A11 M11 ), especially in OC users. A strong association was found between PhL and FVIIa: in the multiple regression analysis, women taking OCs who had elevated PhL concentrations also had very high levels of FVIIa, but only if their genotype was A11 M11 . These results indicate that the increased FVII levels in OC users depend on the FVII genotype and that high PhL concentrations predict very high levels of FVIIa and FVIIc.
Databáze: OpenAIRE